View ValuationCKD Bio 将来の成長Future 基準チェック /06現在、 CKD Bioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長24.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 27CKD Bio Corp., Annual General Meeting, Mar 26, 2026CKD Bio Corp., Annual General Meeting, Mar 26, 2026, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, osong-eup, heungdeok-gu, chungcheongbuk-do, cheongju South Koreaお知らせ • Feb 26CKD Bio Corp., Annual General Meeting, Mar 26, 2025CKD Bio Corp., Annual General Meeting, Mar 26, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, heungdeok-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Minor Risk Market cap is less than US$100m (₩119.6b market cap, or US$85.0m).New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.8b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩132.8b market cap, or US$96.4m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 76% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩122.3b market cap, or US$88.6m).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.1b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 81% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩131.1b market cap, or US$99.2m).Reported Earnings • May 19First quarter 2023 earnings released: ₩530 loss per share (vs ₩220 loss in 1Q 2022)First quarter 2023 results: ₩530 loss per share (further deteriorated from ₩220 loss in 1Q 2022). Revenue: ₩43.7b (down 6.8% from 1Q 2022). Net loss: ₩2.91b (loss widened 141% from 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 17Full year 2022 earnings released: ₩3,045 loss per share (vs ₩1,199 loss in FY 2021)Full year 2022 results: ₩3,045 loss per share (further deteriorated from ₩1,199 loss in FY 2021). Revenue: ₩156.0b (up 9.7% from FY 2021). Net loss: ₩16.7b (loss widened 154% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Upcoming Dividend • Dec 22Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).Reported Earnings • May 23First quarter 2021 earnings released: ₩357 loss per share (vs ₩460 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: ₩33.5b (up 10% from 1Q 2020). Net loss: ₩1.96b (down 179% from profit in 1Q 2020).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₩77,400, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 263% over the past three years.Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩1,147 (vs ₩2,391 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩124.6b (down 9.2% from FY 2019). Net income: ₩6.21b (down 49% from FY 2019). Profit margin: 5.0% (down from 8.9% in FY 2019). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩61,700, the stock is trading at a trailing P/E ratio of 32.3x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 175%.お知らせ • Mar 06CKD Bio Corp., Annual General Meeting, Mar 26, 2021CKD Bio Corp., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Mar 01New 90-day low: ₩65,900The company is down 2.0% from its price of ₩67,400 on 01 December 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.分析記事 • Feb 28What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor CompositionThe big shareholder groups in CKD Bio Corp. ( KRX:063160 ) have power over the company. Large companies usually have...分析記事 • Feb 01Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?It might be of some concern to shareholders to see the CKD Bio Corp. ( KRX:063160 ) share price down 12% in the last...分析記事 • Jan 11CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩77,500, the stock is trading at a trailing P/E ratio of 40.5x, down from the previous P/E ratio of 49x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 288%.Upcoming Dividend • Dec 22Upcoming Dividend of ₩190 Per ShareWill be paid on the 6th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.2% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.6%).分析記事 • Dec 21What CKD Bio Corp.'s (KRX:063160) ROE Can Tell UsWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Is New 90 Day High Low • Dec 18New 90-day high: ₩102,000The company is up 101% from its price of ₩50,700 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩101,000, the stock is trading at a trailing P/E ratio of 52.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 413%.分析記事 • Nov 30Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Is New 90 Day High Low • Nov 30New 90-day high: ₩64,200The company is up 15% from its price of ₩55,800 on 01 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 19% share price gain to ₩64,200, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 201%.Reported Earnings • Nov 22Third quarter 2020 earnings released: EPS ₩252The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩32.7b (down 6.5% from 3Q 2019). Net income: ₩1.36b (down 59% from 3Q 2019). Profit margin: 4.2% (down from 9.5% in 3Q 2019). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 30% share price gain to ₩53,500, the stock is trading at a trailing P/E ratio of 23.3x, up from the previous P/E ratio of 17.9x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 157%.Is New 90 Day High Low • Oct 30New 90-day low: ₩39,250The company is down 1.0% from its price of ₩39,450 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.業績と収益の成長予測KOSE:A063160 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024194,500N/AN/AN/A19/30/2023159,935-23,130-25,355-16,588N/A6/30/2023155,183-20,233-20,483-11,038N/A3/31/2023152,876-18,403-15,290-8,075N/A12/31/2022156,042-16,703-10,435-3,205N/A9/30/2022154,395-10,462-6,8371,239N/A6/30/2022154,759-11,222-10,230721N/A3/31/2022155,569-5,821-15,703-436N/A12/31/2021142,238-6,577-26,588-5,882N/A9/30/2021135,760-6,730-30,532-7,506N/A6/30/2021130,483-1,111-40,416-6,503N/A3/31/2021127,7411,771-52,783-3,114N/A12/31/2020124,6006,207-57,7854,824N/A9/30/2020135,77310,664-61,9036,278N/A6/30/2020138,04212,633-56,65110,401N/A3/31/2020136,26512,446-36,09419,449N/A12/31/2019137,18412,265-30,81716,990N/A9/30/2019129,52910,563-27,62719,152N/A6/30/2019127,1349,605-13,99019,668N/A12/31/2018124,5107,956-1,47715,536N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A063160の予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A063160の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A063160の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A063160の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A063160の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A063160の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 02:54終値2026/08/18 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CKD Bio Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Kyung-rae HanDaishin Securities Co. Ltd.Han Kyung KimLS Securities Co., Ltd.NaYeon KimNH Investment & Securities Co., Ltd.2 その他のアナリストを表示
お知らせ • Feb 27CKD Bio Corp., Annual General Meeting, Mar 26, 2026CKD Bio Corp., Annual General Meeting, Mar 26, 2026, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, osong-eup, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
お知らせ • Feb 26CKD Bio Corp., Annual General Meeting, Mar 26, 2025CKD Bio Corp., Annual General Meeting, Mar 26, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 22, osongsaengmyeong 4-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Minor Risk Market cap is less than US$100m (₩119.6b market cap, or US$85.0m).
New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.8b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩132.8b market cap, or US$96.4m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 76% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩122.3b market cap, or US$88.6m).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.1b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 81% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩131.1b market cap, or US$99.2m).
Reported Earnings • May 19First quarter 2023 earnings released: ₩530 loss per share (vs ₩220 loss in 1Q 2022)First quarter 2023 results: ₩530 loss per share (further deteriorated from ₩220 loss in 1Q 2022). Revenue: ₩43.7b (down 6.8% from 1Q 2022). Net loss: ₩2.91b (loss widened 141% from 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 17Full year 2022 earnings released: ₩3,045 loss per share (vs ₩1,199 loss in FY 2021)Full year 2022 results: ₩3,045 loss per share (further deteriorated from ₩1,199 loss in FY 2021). Revenue: ₩156.0b (up 9.7% from FY 2021). Net loss: ₩16.7b (loss widened 154% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Upcoming Dividend • Dec 22Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
Reported Earnings • May 23First quarter 2021 earnings released: ₩357 loss per share (vs ₩460 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: ₩33.5b (up 10% from 1Q 2020). Net loss: ₩1.96b (down 179% from profit in 1Q 2020).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₩77,400, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 263% over the past three years.
Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩1,147 (vs ₩2,391 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩124.6b (down 9.2% from FY 2019). Net income: ₩6.21b (down 49% from FY 2019). Profit margin: 5.0% (down from 8.9% in FY 2019). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩61,700, the stock is trading at a trailing P/E ratio of 32.3x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 175%.
お知らせ • Mar 06CKD Bio Corp., Annual General Meeting, Mar 26, 2021CKD Bio Corp., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Mar 01New 90-day low: ₩65,900The company is down 2.0% from its price of ₩67,400 on 01 December 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.
分析記事 • Feb 28What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor CompositionThe big shareholder groups in CKD Bio Corp. ( KRX:063160 ) have power over the company. Large companies usually have...
分析記事 • Feb 01Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?It might be of some concern to shareholders to see the CKD Bio Corp. ( KRX:063160 ) share price down 12% in the last...
分析記事 • Jan 11CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩77,500, the stock is trading at a trailing P/E ratio of 40.5x, down from the previous P/E ratio of 49x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 288%.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩190 Per ShareWill be paid on the 6th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.2% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.6%).
分析記事 • Dec 21What CKD Bio Corp.'s (KRX:063160) ROE Can Tell UsWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Is New 90 Day High Low • Dec 18New 90-day high: ₩102,000The company is up 101% from its price of ₩50,700 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩101,000, the stock is trading at a trailing P/E ratio of 52.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 413%.
分析記事 • Nov 30Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Is New 90 Day High Low • Nov 30New 90-day high: ₩64,200The company is up 15% from its price of ₩55,800 on 01 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 19% share price gain to ₩64,200, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 201%.
Reported Earnings • Nov 22Third quarter 2020 earnings released: EPS ₩252The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩32.7b (down 6.5% from 3Q 2019). Net income: ₩1.36b (down 59% from 3Q 2019). Profit margin: 4.2% (down from 9.5% in 3Q 2019). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 30% share price gain to ₩53,500, the stock is trading at a trailing P/E ratio of 23.3x, up from the previous P/E ratio of 17.9x. This compares to an average P/E of 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 157%.
Is New 90 Day High Low • Oct 30New 90-day low: ₩39,250The company is down 1.0% from its price of ₩39,450 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.